Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook
10 nov. 2023 08h05 HE
|
Palisade Bio, Inc.
– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment...